TPC at the ETH Domain Human Health Day 2026
The Tumor Profiler Center took part in the ETH Domain Human Health Day 2026, held on 20 August 2026 at the Rolex Learning Centre at EPFL in Lausanne.
Welcome talk from Prof. Anna Fontcuberta i Morral and Prof. Stéphanie Lacour
Multi-Omics Profiling Alters Treatment Recommendations in 76% of Ovarian Cancer Patients: TPC Study in Nature Communications
Ovarian Cancer Tumor Profiling Resource Published in Nature Communications
The Tumor Profiler Consortium celebrates the publication of a comprehensive multi-omics resource for high-grade serous ovarian cancer (HGSOC) in Nature Communications. The study demonstrates that integrated multimodal tumor profiling can inform personalised maintenance treatment decisions and reveals how chemotherapy reshapes tumour cell diversity.
TPC Safety Study Published in JCO Precision Oncology
Multi-Omics Guidance Safe for Advanced Melanoma Treatment
The Tumor Profiler Consortium celebrates the publication of a comprehensive safety analysis demonstrating that multi-omics-guided therapy selection is safe and feasible for patients with advanced melanoma. The study, published in JCO Precision Oncology, represents the first comparative safety analysis of multi-omics informed therapies.
7th Zurich Precision Oncology Conference 2026
Call for Abstracts Open
The Tumor Profiler Consortium invites the TPC community to participate in the 7th Zurich Precision Oncology Conference 2026, hosted for the first time jointly by the Comprehensive Cancer Center Zurich (CCCZ), The LOOP Zurich, and the Tumor Profiler Center.
Multi-Omics Profiling Proves Cost-Effective
Multi-Omics Profiling Proves Cost-Effective: TPC Melanoma Study Published in npj Precision Oncology
A comprehensive cost analysis from the Tumor Profiler melanoma project has been accepted for publication in npj Precision Oncology. The study demonstrates that multi-omics-guided treatment decisions do not lead to significantly higher treatment costs compared to standard care, addressing a key concern in precision oncology implementation.
Navignostics Wins Swiss Technology Award in Start-ups Category
Navignostics Wins Swiss Technology Award in Start-ups Category
Navignostics, a precision oncology company with roots in TPC-affiliated research, has been awarded the prestigious Swiss Technology Award 2025 in the Start-ups/Rising Stars category. The Tumor Profiler Center extends warm congratulations to the Navignostics team for this outstanding achievement.
Driving Precision Oncology Forward - New Research Initiatives in Zurich
Zurich Expands Precision Oncology in a Pioneering Way – Four New Research Initiatives to Launch in 2026
With a targeted expansion of precision oncology, University of Medicine Zurich (UMZH) is strengthening its leading role in Swiss cancer medicine. Beginning 1 January 2026, four new highly innovative research projects will launch, further paving the way toward individually tailored cancer therapies. The goal is to sustainably improve care for patients in Zurich and across Switzerland.
The University of Medicine Zurich (UMZH) is making targeted investments in strategic centers to strengthen Zurich as a hub for research and innovation and to accelerate the translation of new medical approaches into patient care. Supported institutions include the Comprehensive Cancer Center Zurich (CCCZ), the Tumor Profiler Center (TPC) and The LOOP Zurich. These centers unite top expertise in precision medicine, oncology, data science and translational research, and play a vital role in developing and applying personalized diagnostics and treatment approaches in clinical practice.
Snijder Lab Wins Precision Medicine Award 2025
Snijder Lab Wins Precision Medicine Award 2025 for Pharmacoscopy Technology
The Tumor Profiler Consortium congratulates Prof. Berend Snijder and the Snijder Lab on receiving the Precision Medicine Award 2025 from Oxford Global for "Biggest Technology Impact of the year". The award recognises their pioneering work on pharmacoscopy, a functional precision medicine platform.
HistoPlexer: AI Model Trained on TPC Data Predicts Protein Expression from Routine Pathology
TPC Data Enables AI Model for Predicting Protein Expression from Standard Pathology Images
Research published in Nature Machine Intelligence demonstrates that multimodal data from the Tumor Profiler Center can train artificial intelligence models to predict spatially resolved protein expression patterns directly from routine histopathology slides. The study, published on August 4, 2025, presents HistoPlexer, a deep learning framework with potential to make advanced molecular profiling more accessible in precision oncology.
We use cookies
We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.